Novartis’ MS Drug Patent Upheld And Generic Ruled Infringing

Novartis Pharmaceuticals Corp. beat back a challenge to its blockbuster multiple sclerosis drug Gilenya in a Delaware federal court ruling unsealed on Monday, with the judge finding Novartis’ patent valid and holding that a planned generic by HEC Pharm infringed…

Read this piece in its entirety at Law360.


Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s